CA9 and cancer: Targeting CAIX activity in combination with erastin-mediated inhibition of xCT enhanced ferroptosis in cancer cells in a pH-dependent manner, providing an effective approach to exploiting the synthetic lethal interaction between CAIX and NFS1 using pharmacologic agents (Chafe et al., 2021).